Free Trial
→ Trump’s Exec Order #14154 could be a “Millionaire-Maker” (From Paradigm Press) (Ad) Buy IDYA Stock  Free IDYA Stock Alerts

IDEAYA Biosciences (IDYA) Financials

IDEAYA Biosciences logo
$22.63 +0.92 (+4.24%)
Closing price 04:00 PM Eastern
Extended Trading
$22.61 -0.02 (-0.09%)
As of 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for IDEAYA Biosciences

Annual Income Statements for IDEAYA Biosciences

This table shows IDEAYA Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -34 -42 -35 -50 -59 -113 -274
Consolidated Net Income / (Loss)		 -34 -42 -34 -50 -59 -113 -274
Net Income / (Loss) Continuing Operations		 -34 -42 -34 -50 -59 -113 -274
Total Pre-Tax Income 		-36 -44 -35 -50 -63 -134 -327
Total Operating Income		 -36 -44 -35 -50 -63 -134 -327
Total Gross Profit		 0.00 0.00 20 28 51 23 7.00
Total Revenue		 0.00 0.00 20 28 51 23 7.00
Operating Revenue		 0.00 0.00 20 28 51 23 7.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 36 44 55 78 113 158 334
Selling, General & Admin Expense		 4.67 9.95 15 20 24 28 39
Research & Development Expense		 32 34 40 58 90 130 295
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.51 0.00 0.00 0.00
Other Gains / (Losses), net		 2.07 2.30 0.85 - 3.85 21 52
Basic Earnings per Share		 ($35.92) ($3.36) ($1.40) ($1.41) ($1.42) ($1.96) ($3.36)
Weighted Average Basic Shares Outstanding		 956.25K 12.50M 24.72M 35.25M 41.44M 57.52M 81.68M
Diluted Earnings per Share		 ($35.92) ($3.36) ($1.40) ($1.41) ($1.42) ($1.96) ($3.36)
Weighted Average Diluted Shares Outstanding		 956.25K 12.50M 24.72M 35.25M 41.44M 57.52M 81.68M
Weighted Average Basic & Diluted Shares Outstanding		 956.25K 12.50M 24.72M 35.25M 48.39M 74.56M 87.54M

Quarterly Income Statements for IDEAYA Biosciences

This table shows IDEAYA Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 1.62 -24 -24 -28 -27 -35 -40 -53 -47 -135 -72
Consolidated Net Income / (Loss)		 1.62 -24 -24 -28 -27 -34 -40 -53 -52 -130 -72
Net Income / (Loss) Continuing Operations		 1.62 -24 -24 -28 -27 -34 -40 -53 -52 -130 -72
Total Pre-Tax Income 		1.62 -28 -24 -33 -34 -45 -40 -65 -67 -156 -72
Total Operating Income		 0.66 -26 -26 -33 -34 -42 -51 -65 -67 -144 -84
Total Gross Profit		 30 4.02 7.88 3.54 8.04 3.92 0.00 0.00 0.00 7.00 0.00
Total Revenue		 30 4.02 7.88 3.54 8.04 3.92 0.00 0.00 0.00 7.00 0.00
Operating Revenue		 30 4.02 7.88 3.54 8.04 3.92 0.00 0.00 0.00 7.00 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 29 30 34 36 42 46 51 65 67 151 84
Selling, General & Admin Expense		 6.67 5.75 6.30 7.08 7.86 7.07 8.21 10 9.74 11 14
Research & Development Expense		 22 25 28 29 34 39 43 55 57 140 71
Total Other Income / (Expense), net		 0.96 -1.40 2.64 0.00 0.00 -2.64 11 0.00 0.00 -11 12
Other Income / (Expense), net		 - - 2.64 - - - 11 - - - 12
Basic Earnings per Share		 $0.04 ($0.53) ($0.49) ($0.50) ($0.46) ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82)
Weighted Average Basic Shares Outstanding		 40.30M 41.44M 48.37M 56.25M 60.00M 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M
Diluted Earnings per Share		 $0.04 ($0.53) ($0.49) ($0.50) ($0.46) ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82)
Weighted Average Diluted Shares Outstanding		 41.11M 41.44M 48.37M 56.25M 60.00M 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M
Weighted Average Basic & Diluted Shares Outstanding		 48.11M 48.39M - 57.56M 64.46M 74.56M 75.69M 84.48M 86.43M 87.54M 87.58M

Annual Cash Flow Statements for IDEAYA Biosciences

This table details how cash moves in and out of IDEAYA Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 15 14 38 20 -23 89 -73
Net Cash From Operating Activities		 -28 -39 55 -56 -87 -115 -248
Net Cash From Continuing Operating Activities		 -28 -39 55 -56 -87 -115 -248
Net Income / (Loss) Continuing Operations		 -34 -42 -34 -50 -59 -113 -274
Consolidated Net Income / (Loss)		 -34 -42 -34 -50 -59 -113 -274
Depreciation Expense		 0.89 1.25 1.38 1.73 2.10 2.48 2.39
Amortization Expense		 -0.81 -0.47 0.58 3.14 0.72 -10 -22
Non-Cash Adjustments To Reconcile Net Income		 4.99 3.27 3.59 -15 -35 4.74 35
Changes in Operating Assets and Liabilities, net		 1.65 -1.38 84 4.42 3.51 0.55 12
Net Cash From Investing Activities		 -63 2.27 -146 -70 -33 -158 -503
Net Cash From Continuing Investing Activities		 -63 2.27 -146 -70 -33 -158 -503
Purchase of Property, Plant & Equipment		 -1.71 -1.35 -0.49 -2.64 -3.44 -2.37 -3.86
Purchase of Investments		 -133 -88 -242 -315 -256 -596 -1,191
Sale and/or Maturity of Investments		 72 92 97 248 226 440 693
Net Cash From Financing Activities		 105 51 129 145 97 363 678
Net Cash From Continuing Financing Activities		 105 51 129 145 97 363 678
Issuance of Common Equity		 0.00 50 128 144 96 353 665
Other Financing Activities, net		 0.09 0.29 1.19 1.50 1.45 9.56 12
Cash Interest Paid		 0.10 0.09 0.08 0.07 0.06 0.07 0.03
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for IDEAYA Biosciences

This table details how cash moves in and out of IDEAYA Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 53 -33 -1.40 36 49 5.20 -49 75 217 -316 46
Net Cash From Operating Activities		 -24 -23 -28 -33 -30 -24 -44 -33 -49 -122 -60
Net Cash From Continuing Operating Activities		 -24 -23 -28 -33 -30 -24 -44 -33 -49 -122 -60
Net Income / (Loss) Continuing Operations		 1.62 -24 -24 -28 -27 -34 -40 -53 -52 -130 -72
Consolidated Net Income / (Loss)		 1.62 -24 -24 -28 -27 -34 -40 -53 -52 -130 -72
Depreciation Expense		 0.57 0.56 0.59 0.62 0.64 0.63 0.62 0.62 0.58 0.57 0.60
Amortization Expense		 0.27 -0.76 -1.19 -2.18 -3.18 -3.48 -5.85 -6.17 -4.93 -4.85 -3.25
Non-Cash Adjustments To Reconcile Net Income		 3.01 -44 3.66 4.73 5.30 -8.96 6.31 9.73 9.22 9.49 10
Changes in Operating Assets and Liabilities, net		 -30 45 -7.26 -8.71 -5.50 22 -5.32 16 -2.28 3.45 4.24
Net Cash From Investing Activities		 -19 -10 24 -121 51 -112 -354 69 -20 -197 80
Net Cash From Continuing Investing Activities		 -19 -10 24 -121 51 -112 -354 69 -20 -197 80
Purchase of Property, Plant & Equipment		 -1.10 - -0.04 -0.88 -0.60 -0.84 -1.33 -0.97 -0.46 -1.10 -1.33
Purchase of Investments		 -88 -66 -72 -220 -82 -222 -476 -165 -214 -337 -105
Sale and/or Maturity of Investments		 71 55 96 100 134 111 123 234 194 141 186
Net Cash From Financing Activities		 96 0.32 2.93 191 28 141 349 39 287 2.75 26
Net Cash From Continuing Financing Activities		 96 0.32 2.93 191 28 141 349 39 287 2.75 26
Issuance of Common Equity		 95 -0.19 2.56 190 26 135 344 37 284 0.25 25
Other Financing Activities, net		 0.50 0.52 0.37 1.49 1.86 5.85 5.46 2.08 2.44 2.50 1.13
Cash Interest Paid		 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.00 - 0.00

Annual Balance Sheets for IDEAYA Biosciences

This table presents IDEAYA Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 97 113 298 381 388 649 1,124
Total Current Assets		 91 102 289 251 370 533 690
Cash & Equivalents		 21 34 72 92 69 157 84
Short-Term Investments		 69 65 212 155 296 368 592
Accounts Receivable		 - 0.00 1.88 1.10 0.21 0.02 0.00
Prepaid Expenses		 0.71 2.70 3.14 3.12 5.41 7.50 13
Plant, Property, & Equipment, net		 5.15 4.64 4.27 4.76 6.51 6.16 8.97
Total Noncurrent Assets		 0.72 6.71 5.39 126 11 111 425
Long-Term Investments		 - 1.53 0.00 121 8.32 107 406
Other Noncurrent Operating Assets		 0.72 5.18 5.39 4.30 2.69 3.03 20
Total Liabilities & Shareholders' Equity		 97 113 298 381 388 649 1,124
Total Liabilities		 7.10 13 100 80 39 28 65
Total Current Liabilities		 5.41 6.94 39 45 32 27 46
Accounts Payable		 1.42 0.71 0.95 2.10 4.28 6.60 15
Accrued Expenses		 3.58 5.02 8.52 12 17 19 30
Current Deferred Revenue		 0.30 0.00 28 29 8.57 0.00 0.00
Other Current Liabilities		 0.11 1.21 1.56 1.70 1.87 1.75 0.30
Total Noncurrent Liabilities		 1.69 5.66 61 35 6.80 1.13 19
Noncurrent Deferred Revenue		 1.57 0.00 56 31 5.19 0.00 0.00
Other Noncurrent Operating Liabilities		 0.11 5.66 5.20 3.48 1.61 1.13 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -49 100 198 302 349 621 1,059
Total Preferred & Common Equity		 -49 100 198 302 349 621 1,059
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -49 100 198 302 349 621 1,059
Common Stock		 1.60 193 325 479 588 969 1,681
Retained Earnings		 -51 -92 -127 -177 -235 -348 -623
Accumulated Other Comprehensive Income / (Loss)		 -0.03 0.07 0.01 -0.71 -2.87 0.56 0.81

Quarterly Balance Sheets for IDEAYA Biosciences

This table presents IDEAYA Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 411 365 528 533 962 974 1,240 1,101
Total Current Assets		 393 344 502 482 709 713 932 708
Cash & Equivalents		 102 67 103 152 108 183 400 130
Short-Term Investments		 284 272 391 317 590 519 520 563
Accounts Receivable		 3.45 0.47 0.16 6.70 0.02 0.00 0.02 0.00
Prepaid Expenses		 3.74 4.02 7.91 6.73 11 12 12 15
Plant, Property, & Equipment, net		 6.68 6.72 6.83 6.19 6.91 7.12 8.24 8.87
Total Noncurrent Assets		 11 14 19 45 245 253 299 384
Long-Term Investments		 7.69 12 16 42 243 251 280 359
Other Noncurrent Operating Assets		 3.10 2.33 2.56 2.17 2.63 2.29 19 25
Total Liabilities & Shareholders' Equity		 411 365 528 533 962 974 1,240 1,101
Total Liabilities		 42 31 26 25 26 42 59 77
Total Current Liabilities		 33 30 25 25 25 41 41 51
Accounts Payable		 3.65 4.38 5.87 5.17 6.29 16 13 18
Accrued Expenses		 17 17 15 16 18 24 28 33
Other Current Liabilities		 1.83 1.92 1.96 2.10 1.15 0.61 0.00 0.31
Total Noncurrent Liabilities		 9.41 1.12 0.61 0.00 1.26 1.26 19 26
Other Noncurrent Operating Liabilities		 2.10 1.12 0.61 0.00 1.26 1.26 19 26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 369 334 502 508 935 932 1,180 1,024
Total Preferred & Common Equity		 369 334 502 508 935 932 1,180 1,024
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 369 334 502 508 935 932 1,180 1,024
Common Stock		 584 594 790 823 1,324 1,374 1,669 1,718
Retained Earnings		 -211 -259 -287 -314 -388 -441 -493 -695
Accumulated Other Comprehensive Income / (Loss)		 -4.00 -1.41 -1.18 -0.75 -0.92 -1.42 3.84 1.59

Annual Metrics And Ratios for IDEAYA Biosciences

This table displays calculated financial ratios and metrics derived from IDEAYA Biosciences' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 43.01% 82.28% -54.08% -70.07%
EBITDA Growth		 0.00% -19.70% 23.25% -34.48% -32.93% -137.88% -143.97%
EBIT Growth		 0.00% -21.57% 20.16% -40.79% -25.60% -115.08% -143.23%
NOPAT Growth		 0.00% -21.57% 20.16% -42.23% -24.34% -115.08% -143.23%
Net Income Growth		 0.00% -22.21% 17.82% -44.26% -17.87% -92.59% -142.98%
EPS Growth		 0.00% 90.65% 58.33% -0.71% -0.71% -38.03% -71.43%
Operating Cash Flow Growth		 0.00% -42.34% 241.08% -200.57% -56.29% -32.18% -114.87%
Free Cash Flow Firm Growth		 0.00% 0.00% 292.48% -189.19% -60.54% -22.71% -104.56%
Invested Capital Growth		 0.00% 84.17% -103,937.80% 21.99% 64.40% 51.39% -99.76%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -21.40% 2.13% -0.42% 78.43%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -36.93% -19.01% -14.63% -42.70%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -33.84% -14.83% -13.01% -45.48%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -35.21% -14.83% -13.01% -45.48%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -35.65% -11.37% -9.45% -54.10%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -45.36% -2.90% 1.01% -44.83%
Operating Cash Flow Q/Q Growth		 0.00% -3.23% -4.95% -9.98% -8.34% -0.33% -65.41%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -6.83% -0.89% -54.53%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 2.33% 5.86% -271.96% -16.54%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -170.87% -160.68% -117.18% -607.12% -4,948.20%
Operating Margin		 0.00% 0.00% -180.90% -179.91% -122.72% -574.85% -4,671.07%
EBIT Margin		 0.00% 0.00% -180.90% -178.10% -122.72% -574.85% -4,671.07%
Profit (Net Income) Margin		 0.00% 0.00% -176.55% -178.10% -115.17% -483.05% -3,921.10%
Tax Burden Percent		 94.31% 94.81% 97.60% 100.00% 93.85% 84.03% 83.94%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -38.40% -44.22% -23.10% -19.91% -18.02% -23.28% -32.67%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -17.19% -14.64% -16.25% -25.92% -36.88%
Return on Assets (ROA)		 0.00% 0.00% -16.77% -14.64% -15.25% -21.78% -30.95%
Return on Common Equity (ROCE)		 21.01% -11.98% -23.10% -19.91% -18.02% -23.28% -32.67%
Return on Equity Simple (ROE_SIMPLE)		 70.17% -41.81% -17.40% -16.50% -16.78% -18.19% -25.91%
Net Operating Profit after Tax (NOPAT)		 -25 -31 -25 -35 -44 -94 -229
NOPAT Margin		 0.00% 0.00% -126.63% -125.94% -85.90% -402.40% -3,269.75%
Net Nonoperating Expense Percent (NNEP)		 -9.84% -11.54% -5.08% -4.47% -4.02% -3.75% -5.32%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -12.52% -15.15% -21.61%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 77.72% 71.76% 46.92% 121.04% 561.46%
R&D to Revenue		 0.00% 0.00% 203.18% 208.15% 175.80% 553.81% 4,209.61%
Operating Expenses to Revenue		 0.00% 0.00% 280.90% 279.91% 222.72% 674.85% 4,771.07%
Earnings before Interest and Taxes (EBIT)		 -36 -44 -35 -50 -63 -134 -327
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -43 -33 -45 -60 -142 -346
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 1.52 2.05 3.02 2.50 3.69 2.10
Price to Tangible Book Value (P/TBV)		 0.00 1.52 2.05 3.02 2.50 3.69 2.10
Price to Revenue (P/Rev)		 0.00 0.00 20.83 32.57 17.16 98.07 317.33
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 6.32 19.40 9.84 71.02 162.74
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 2.22 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 2.04 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.00 -1.29 -1.30 -1.14 -1.04 -1.02
Leverage Ratio		 1.08 1.10 1.38 1.36 1.18 1.07 1.06
Compound Leverage Factor		 1.08 1.10 1.38 1.36 1.18 1.07 1.06
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 154.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -54.73% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.31 5.83 2.53 6.48 13.42 48.29 19.48
Noncontrolling Interest Sharing Ratio		 154.73% 72.90% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 16.75 14.65 7.47 5.56 11.68 19.65 14.97
Quick Ratio		 16.62 14.26 7.39 5.49 11.51 19.38 14.68
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -31 60 -54 -87 -106 -217
Operating Cash Flow to CapEx		 -1,617.10% -2,905.62% 11,250.10% -2,109.64% -2,531.95% -4,865.88% -6,419.08%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.10 0.08 0.13 0.05 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 18.75 77.52 204.24 666.67
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 4.38 6.19 9.04 3.69 0.93
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 19.46 4.71 1.79 0.55
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 19.46 4.71 1.79 0.55
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -0.52 -0.08 -85 -67 -24 -12 -23
Invested Capital Turnover		 0.00 0.00 -0.46 -0.37 -1.13 -1.33 -0.41
Increase / (Decrease) in Invested Capital		 0.00 0.44 -85 19 43 12 -11
Enterprise Value (EV)		 98 52 123 542 501 1,661 1,139
Market Capitalization		 50 152 407 910 874 2,293 2,221
Book Value per Share		 ($51.19) $4.94 $6.82 $7.83 $7.26 $9.64 $12.25
Tangible Book Value per Share		 ($51.19) $4.94 $6.82 $7.83 $7.26 $9.64 $12.25
Total Capital		 89 100 198 302 349 621 1,059
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -90 -100 -284 -368 -373 -633 -1,082
Capital Expenditures (CapEx)		 1.71 1.35 0.49 2.64 3.44 2.37 3.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.71 -4.24 -34 -41 -26 -20 -33
Debt-free Net Working Capital (DFNWC)		 85 95 250 206 339 506 644
Net Working Capital (NWC)		 85 95 250 206 339 506 644
Net Nonoperating Expense (NNE)		 8.85 11 9.75 15 15 19 46
Net Nonoperating Obligations (NNO)		 -90 -100 -284 -368 -373 -633 -1,082
Total Depreciation and Amortization (D&A)		 0.08 0.77 1.96 4.87 2.82 -7.55 -19
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -172.07% -146.50% -51.23% -83.74% -466.81%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,279.38% 736.68% 665.09% 2,161.77% 9,194.89%
Net Working Capital to Revenue		 0.00% 0.00% 1,279.38% 736.68% 665.09% 2,161.77% 9,194.89%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.40) ($1.41) ($1.42) ($1.96) ($3.36)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 32.26M 38.63M 41.44M 57.52M 81.68M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.40) ($1.41) ($1.42) ($1.96) ($3.36)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 32.26M 38.63M 41.44M 57.52M 81.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.40) ($1.41) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 24.72M 35.25M 48.39M 74.56M 87.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -31 -25 -35 -44 -94 -229
Normalized NOPAT Margin		 0.00% 0.00% -126.63% -125.94% -85.90% -402.40% -3,269.75%
Pre Tax Income Margin		 0.00% 0.00% -180.90% -178.10% -122.72% -574.85% -4,671.07%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for IDEAYA Biosciences

This table displays calculated financial ratios and metrics derived from IDEAYA Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 230.87% 35.79% -30.63% -39.43% -72.94% -2.46% -100.00% -100.00% -100.00% 78.43% 0.00%
EBITDA Growth		 114.50% -55.69% -85.54% -62.96% -2,506.00% -67.99% -84.86% -105.66% -97.54% -231.52% -33.02%
EBIT Growth		 105.70% -43.95% -66.24% -48.30% -5,179.70% -58.51% -67.39% -98.50% -99.53% -243.88% -41.48%
NOPAT Growth		 108.05% -43.95% -84.80% -45.38% -3,655.79% -58.51% -94.14% -98.50% -99.53% -243.88% -65.41%
Net Income Growth		 113.94% -32.88% -68.70% -26.61% -1,799.07% -40.30% -67.39% -88.97% -88.85% -283.78% -82.40%
EPS Growth		 112.90% -8.16% -36.11% 12.28% -1,250.00% 3.77% -8.16% -36.00% -30.43% -203.92% -54.72%
Operating Cash Flow Growth		 -93.82% -40.30% -41.71% -67.37% -24.86% -1.62% -57.36% 1.73% -63.17% -412.27% -37.73%
Free Cash Flow Firm Growth		 -26.41% -94.08% -97.36% -105.93% -7.62% 32.35% 19.71% 52.29% 33.72% -115.36% 18.90%
Invested Capital Growth		 63.07% 64.40% 69.77% 84.42% 87.70% 51.39% 64.96% -148.36% -537.56% -99.76% -343.46%
Revenue Q/Q Growth		 407.59% -86.46% 95.92% -55.03% 126.81% -51.19% -100.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 107.13% -1,877.72% 9.05% -41.37% -5.26% -24.13% -0.08% -57.29% -1.10% -108.31% 49.58%
EBIT Q/Q Growth		 102.99% -4,106.52% 10.60% -38.36% -2.50% -25.02% 5.59% -64.07% -3.03% -115.48% 49.92%
NOPAT Q/Q Growth		 104.19% -2,904.56% 0.62% -24.47% -2.50% -25.02% -21.72% -27.27% -3.03% -115.48% 41.45%
Net Income Q/Q Growth		 107.32% -1,598.51% 2.32% -18.13% 1.74% -23.74% -16.54% -33.36% 1.80% -151.47% 44.61%
EPS Q/Q Growth		 107.02% -1,425.00% 7.55% -2.04% 8.00% -10.87% -3.92% -28.30% 11.76% -158.33% 47.10%
Operating Cash Flow Q/Q Growth		 -20.88% 3.29% -19.14% -20.18% 9.82% 21.30% -84.49% 24.95% -49.73% -147.10% 50.40%
Free Cash Flow Firm Q/Q Growth		 -26.50% -45.03% 4.58% -17.64% 33.89% 8.83% -13.25% 30.10% 8.15% -196.23% 57.35%
Invested Capital Q/Q Growth		 53.80% 5.86% 26.55% 51.24% 63.51% -271.96% 47.06% -245.60% 6.32% -16.54% -17.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 5.05% -662.56% -307.58% -966.85% -448.69% -1,141.14% 0.00% 0.00% 0.00% -2,120.16% 0.00%
Operating Margin		 2.22% -657.46% -333.49% -922.94% -417.09% -1,068.44% 0.00% 0.00% 0.00% -2,059.11% 0.00%
EBIT Margin		 2.22% -657.46% -300.00% -922.94% -417.09% -1,068.44% 0.00% 0.00% 0.00% -2,059.11% 0.00%
Profit (Net Income) Margin		 5.44% -601.72% -300.00% -787.98% -341.38% -865.54% 0.00% 0.00% 0.00% -1,861.60% 0.00%
Tax Burden Percent		 100.00% 86.93% 100.00% 85.38% 81.85% 76.21% 100.00% 81.28% 77.47% 83.76% 100.00%
Interest Burden Percent		 244.70% 105.29% 100.00% 100.00% 100.00% 106.30% 100.00% 100.00% 100.00% 107.94% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -15.35% -18.02% -21.94% -19.24% -23.54% -23.28% -20.31% -21.45% -21.10% -32.67% -31.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.27% -87.05% -39.35% -96.28% -20.76% -48.17% 0.00% 0.00% 0.00% -16.26% 0.00%
Return on Assets (ROA)		 0.67% -79.67% -39.35% -82.20% -16.99% -39.03% 0.00% 0.00% 0.00% -14.70% 0.00%
Return on Common Equity (ROCE)		 -15.35% -18.02% -21.94% -19.24% -23.54% -23.28% -20.31% -21.45% -21.10% -32.67% -31.34%
Return on Equity Simple (ROE_SIMPLE)		 -14.28% 0.00% -20.46% -14.78% -20.31% 0.00% -13.78% -16.50% -15.09% 0.00% -29.98%
Net Operating Profit after Tax (NOPAT)		 0.66 -19 -18 -23 -23 -29 -36 -45 -47 -101 -59
NOPAT Margin		 2.22% -460.22% -233.44% -646.06% -291.97% -747.91% 0.00% 0.00% 0.00% -1,441.38% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.25% -1.54% -1.50% -1.21% -0.88% -0.92% -0.60% -1.00% -0.58% -3.43% -1.32%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.30% - - - -4.72% - - - -9.53% -5.77%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 22.45% 143.04% 79.95% 199.63% 97.82% 180.17% 0.00% 0.00% 0.00% 156.50% 0.00%
R&D to Revenue		 75.33% 614.42% 353.54% 823.31% 419.27% 988.27% 0.00% 0.00% 0.00% 2,002.61% 0.00%
Operating Expenses to Revenue		 97.78% 757.46% 433.49% 1,022.94% 517.09% 1,168.44% 0.00% 0.00% 0.00% 2,159.11% 0.00%
Earnings before Interest and Taxes (EBIT)		 0.66 -26 -24 -33 -34 -42 -40 -65 -67 -144 -72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.50 -27 -24 -34 -36 -45 -45 -70 -71 -148 -75
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.59 2.50 1.99 2.27 3.06 3.69 3.02 2.85 2.27 2.10 1.40
Price to Tangible Book Value (P/TBV)		 1.59 2.50 1.99 2.27 3.06 3.69 3.02 2.85 2.27 2.10 1.40
Price to Revenue (P/Rev)		 11.76 17.16 14.00 25.19 66.13 98.07 182.42 222.17 682.23 317.33 204.84
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.86 9.84 6.60 13.89 44.36 71.02 121.71 142.52 376.30 162.74 54.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.14 -1.14 -1.12 -1.08 -1.03 -1.04 -1.02 -1.02 -1.01 -1.02 -1.02
Leverage Ratio		 1.18 1.18 1.16 1.12 1.08 1.07 1.05 1.05 1.05 1.06 1.05
Compound Leverage Factor		 2.89 1.24 1.16 1.12 1.08 1.14 1.05 1.05 1.05 1.14 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 8.81 13.72 12.84 26.50 37.47 48.76 64.90 37.95 27.14 20.02 10.87
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.02 11.68 11.53 19.80 19.37 19.65 28.42 17.50 22.93 14.97 13.92
Quick Ratio		 11.91 11.51 11.40 19.49 19.10 19.38 28.00 17.22 22.63 14.68 13.62
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -42 -61 -59 -69 -46 -42 -47 -33 -30 -89 -38
Operating Cash Flow to CapEx		 -2,194.91% 0.00% -64,748.84% -3,785.07% -5,003.98% -2,833.89% -3,306.64% -3,379.45% -10,773.30% -11,039.47% -4,536.99%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.12 0.13 0.13 0.10 0.05 0.05 0.02 0.02 0.00 0.01 0.01
Accounts Receivable Turnover		 22.33 77.52 81.46 201.54 4.63 204.24 64.20 148.58 1.17 666.67 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 8.76 9.04 7.92 6.45 3.65 3.69 2.28 1.71 0.54 0.93 0.89
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 16.35 4.71 4.48 1.81 78.89 1.79 5.69 2.46 312.76 0.55 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 16.35 4.71 4.48 1.81 78.89 1.79 5.69 2.46 312.76 0.55 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -25 -24 -17 -8.48 -3.10 -12 -6.10 -21 -20 -23 -27
Invested Capital Turnover		 -1.07 -1.13 -1.27 -1.43 -1.66 -1.33 -1.32 -0.81 -0.34 -0.41 -0.42
Increase / (Decrease) in Invested Capital		 43 43 40 46 22 12 11 -13 -17 -11 -21
Enterprise Value (EV)		 193 501 313 627 1,042 1,661 1,887 1,705 1,476 1,139 383
Market Capitalization		 586 874 664 1,137 1,553 2,293 2,828 2,657 2,676 2,221 1,434
Book Value per Share		 $9.38 $7.26 $6.90 $8.92 $8.83 $9.64 $12.45 $12.31 $13.97 $12.25 $11.70
Tangible Book Value per Share		 $9.38 $7.26 $6.90 $8.92 $8.83 $9.64 $12.45 $12.31 $13.97 $12.25 $11.70
Total Capital		 369 349 334 502 508 621 935 932 1,180 1,059 1,024
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -394 -373 -351 -510 -511 -633 -941 -953 -1,200 -1,082 -1,051
Capital Expenditures (CapEx)		 1.10 0.00 0.04 0.88 0.60 0.84 1.33 0.97 0.46 1.10 1.33
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -26 -26 -25 -17 -11 -20 -14 -29 -28 -33 -35
Debt-free Net Working Capital (DFNWC)		 361 339 314 476 457 506 684 672 892 644 657
Net Working Capital (NWC)		 361 339 314 476 457 506 684 672 892 644 657
Net Nonoperating Expense (NNE)		 -0.96 5.69 5.24 5.03 3.97 4.61 3.86 7.32 5.00 29 13
Net Nonoperating Obligations (NNO)		 -394 -373 -351 -510 -511 -633 -941 -953 -1,200 -1,082 -1,051
Total Depreciation and Amortization (D&A)		 0.84 -0.21 -0.60 -1.56 -2.54 -2.85 -5.23 -5.54 -4.35 -4.27 -2.65
Debt-free, Cash-free Net Working Capital to Revenue		 -51.20% -51.23% -53.38% -38.24% -48.81% -83.74% -92.74% -244.30% -725.82% -466.81% -506.89%
Debt-free Net Working Capital to Revenue		 723.29% 665.09% 662.01% 1,055.38% 1,947.24% 2,161.77% 4,414.01% 5,621.91% 22,726.36% 9,194.89% 9,386.09%
Net Working Capital to Revenue		 723.29% 665.09% 662.01% 1,055.38% 1,947.24% 2,161.77% 4,414.01% 5,621.91% 22,726.36% 9,194.89% 9,386.09%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.04 ($0.53) ($0.49) ($0.50) ($0.46) ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82)
Adjusted Weighted Average Basic Shares Outstanding		 40.30M 41.44M 48.37M 56.25M 60.00M 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M
Adjusted Diluted Earnings per Share		 $0.04 ($0.53) ($0.49) ($0.50) ($0.46) ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82)
Adjusted Weighted Average Diluted Shares Outstanding		 41.11M 41.44M 48.37M 56.25M 60.00M 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 48.11M 48.39M 0.00 57.56M 64.46M 74.56M 75.69M 84.48M 86.43M 87.54M 87.58M
Normalized Net Operating Profit after Tax (NOPAT)		 0.46 -19 -18 -23 -23 -29 -36 -45 -47 -101 -59
Normalized NOPAT Margin		 1.56% -460.22% -233.44% -646.06% -291.97% -747.91% 0.00% 0.00% 0.00% -1,441.38% 0.00%
Pre Tax Income Margin		 5.44% -692.22% -300.00% -922.94% -417.09% -1,135.71% 0.00% 0.00% 0.00% -2,222.61% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About IDEAYA Biosciences' Financials

When does IDEAYA Biosciences's financial year end?

According to the most recent income statement we have on file, IDEAYA Biosciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has IDEAYA Biosciences' net income changed over the last 6 years?

IDEAYA Biosciences' net income appears to be on an upward trend, with a most recent value of -$274.48 million in 2024, rising from -$34.35 million in 2018. The previous period was -$112.96 million in 2023. Check out IDEAYA Biosciences' forecast to explore projected trends and price targets.

What is IDEAYA Biosciences's operating income?
IDEAYA Biosciences's total operating income in 2024 was -$326.98 million, based on the following breakdown:
  • Total Gross Profit: $7 million
  • Total Operating Expenses: $333.98 million
How has IDEAYA Biosciences revenue changed over the last 6 years?

Over the last 6 years, IDEAYA Biosciences' total revenue changed from $0.00 in 2018 to $7 million in 2024, a change of 700,000,000.0%.

How much debt does IDEAYA Biosciences have?

IDEAYA Biosciences' total liabilities were at $64.94 million at the end of 2024, a 130.1% increase from 2023, and a 815.0% increase since 2018.

How much cash does IDEAYA Biosciences have?

In the past 6 years, IDEAYA Biosciences' cash and equivalents has ranged from $20.51 million in 2018 to $157.02 million in 2023, and is currently $84.38 million as of their latest financial filing in 2024.

How has IDEAYA Biosciences' book value per share changed over the last 6 years?

Over the last 6 years, IDEAYA Biosciences' book value per share changed from -51.19 in 2018 to 12.25 in 2024, a change of -123.9%.


Related Companies

This page (NASDAQ:IDYA) was last updated on 6/10/2025 by MarketBeat.com Staff
From Our Partners
Banks aren’t ready for this altcoin—are you?
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...
Crypto 101 Media | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored
Trump Nominates “Next Elon”
Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...
Altimetry | Sponsored
Get Ready for Elon Musk’s BIGGEST Comeback Yet
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...
Brownstone Research | Sponsored
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...
American Alternative | Sponsored
Big Changes Coming to Social Security?
According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...
InvestorPlace | Sponsored
SHOCKING: Musk's Pentagon Secret Mission...
It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...
Behind the Markets | Sponsored